[go: up one dir, main page]

CU23475A1 - Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas - Google Patents

Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas

Info

Publication number
CU23475A1
CU23475A1 CU20040147A CU20040147A CU23475A1 CU 23475 A1 CU23475 A1 CU 23475A1 CU 20040147 A CU20040147 A CU 20040147A CU 20040147 A CU20040147 A CU 20040147A CU 23475 A1 CU23475 A1 CU 23475A1
Authority
CU
Cuba
Prior art keywords
composition
polypeptide fragments
serralisine
pharmaceutical composition
tumor
Prior art date
Application number
CU20040147A
Other languages
English (en)
Inventor
Lopez Luis Javier Gonzalez
Gonzalez Caridad Anais Gasmuri
Diaz Eduardo Martinez
Romero Monica Bequet
Riera Raul Gomez
Gonzalez Jesus Reyes
Perez Maria Del Carmen Abrahantes
Sosa Manuel Selman-Housein
Rio Gloria Veliz
Cowley Jorge Victor Gavilondo
Serra Lila Rosa Castellanos
Suarez Jose Garcia
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20040147A priority Critical patent/CU23475A1/es
Priority to RU2007104776/13A priority patent/RU2396274C2/ru
Priority to AU2005262159A priority patent/AU2005262159B2/en
Priority to RS20120391A priority patent/RS52448B/sr
Priority to JP2007519599A priority patent/JP4914350B2/ja
Priority to PL05762122T priority patent/PL1787653T3/pl
Priority to PT05762122T priority patent/PT1787653E/pt
Priority to PCT/CU2005/000003 priority patent/WO2006005268A2/es
Priority to KR1020077002589A priority patent/KR101365056B1/ko
Priority to US11/631,880 priority patent/US8076297B2/en
Priority to BRPI0513136-7A priority patent/BRPI0513136A/pt
Priority to DK05762122.9T priority patent/DK1787653T3/da
Priority to MX2007000339A priority patent/MX2007000339A/es
Priority to ES05762122T priority patent/ES2389126T3/es
Priority to EP05762122A priority patent/EP1787653B1/en
Priority to HRP20120682TT priority patent/HRP20120682T1/hr
Priority to CA2572984A priority patent/CA2572984C/en
Priority to SI200531578T priority patent/SI1787653T1/sl
Priority to MYPI20053102 priority patent/MY150858A/en
Priority to ARP050102834A priority patent/AR050255A1/es
Priority to ZA200700178A priority patent/ZA200700178B/xx
Publication of CU23475A1 publication Critical patent/CU23475A1/es
Priority to CY20121100800T priority patent/CY1114201T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/265—Enterobacter (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está relacionada con una composición capaz de inhibir el crecimiento de células tumorales de diferentes orígenes histológicos y de célulasendoteliales activadas. Lo scomponentes de dicha composición son fragmentos polipeptídicos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molécula los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto antitumoral de la composición. Las prodigiosinas en la composición pueden estar a ubna concentración de 0.1-100nM. La acción anti-proliferativa de la composición está mediada por mecanismos apoptóticos. Su administración " in vivo" tiene efecto anti-tumoral, antiangiogénico y protecdtor contra tumores malignos.
CU20040147A 2004-07-08 2004-07-08 Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas CU23475A1 (es)

Priority Applications (22)

Application Number Priority Date Filing Date Title
CU20040147A CU23475A1 (es) 2004-07-08 2004-07-08 Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
MX2007000339A MX2007000339A (es) 2004-07-08 2005-07-05 Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas.
DK05762122.9T DK1787653T3 (da) 2004-07-08 2005-07-05 Antitumoral farmaceutisk sammensætning indeholdende polypeptidfragmenter af serralysiner
RS20120391A RS52448B (sr) 2004-07-08 2005-07-05 Antitumorska farmaceutska kompozicija koja sadrži polipeptidne fragmente seralizina
JP2007519599A JP4914350B2 (ja) 2004-07-08 2005-07-05 セラリシン（Ｓｅｒｒａｌｉｓｉｎｓ）のポリペプチド断片を含む医薬組成物
PL05762122T PL1787653T3 (pl) 2004-07-08 2005-07-05 Przeciwnowotworowa kompozycja farmaceutyczna zawierająca fragmenty polipeptydowe serralizyn
PT05762122T PT1787653E (pt) 2004-07-08 2005-07-05 Composição farmacêutica contendo fragmentos de polipéptidos de serralisinas
PCT/CU2005/000003 WO2006005268A2 (es) 2004-07-08 2005-07-05 Composición farmacéutica conteniendo fragmentos polipéptidicos de serralisinas
KR1020077002589A KR101365056B1 (ko) 2004-07-08 2005-07-05 세라리신의 폴리펩티드 분획을 포함하는 약학적 조성물
US11/631,880 US8076297B2 (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins
ES05762122T ES2389126T3 (es) 2004-07-08 2005-07-05 Composición farmacéutica antitumoral que contiene fragmentos polipeptídicos de serralisinas
RU2007104776/13A RU2396274C2 (ru) 2004-07-08 2005-07-05 Противоопухолевая фармацевтическая композиция (варианты) и ее применение
AU2005262159A AU2005262159B2 (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins
BRPI0513136-7A BRPI0513136A (pt) 2004-07-08 2005-07-05 composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas
EP05762122A EP1787653B1 (en) 2004-07-08 2005-07-05 Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins
HRP20120682TT HRP20120682T1 (hr) 2004-07-08 2005-07-05 Protutumorski farmaceutski sastav koji sadr“i polipeptidne fragmente od seralizina
CA2572984A CA2572984C (en) 2004-07-08 2005-07-05 A pharmaceutical composition containing polypeptide fragments of the serralysins
SI200531578T SI1787653T1 (sl) 2004-07-08 2005-07-05 Protitumorski farmacevtski sestavek, ki vsebuje polipeptidne fragmente seralizinov
MYPI20053102 MY150858A (en) 2004-07-08 2005-07-07 A pharmaceutical composition containing polypeptide fragments of the serralysins
ARP050102834A AR050255A1 (es) 2004-07-08 2005-07-08 Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas
ZA200700178A ZA200700178B (en) 2004-07-08 2007-01-05 Pharmaceutical composition containing polypeptide fragments of serralysins
CY20121100800T CY1114201T1 (el) 2004-07-08 2012-09-05 Αντιογκογονικη φαρμακευτικη συνθεση που περιεχει θραυσματα πολυπεπτιδιων σερραλυσινων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040147A CU23475A1 (es) 2004-07-08 2004-07-08 Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas

Publications (1)

Publication Number Publication Date
CU23475A1 true CU23475A1 (es) 2009-12-17

Family

ID=40259088

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040147A CU23475A1 (es) 2004-07-08 2004-07-08 Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas

Country Status (22)

Country Link
US (1) US8076297B2 (es)
EP (1) EP1787653B1 (es)
JP (1) JP4914350B2 (es)
KR (1) KR101365056B1 (es)
AR (1) AR050255A1 (es)
AU (1) AU2005262159B2 (es)
BR (1) BRPI0513136A (es)
CA (1) CA2572984C (es)
CU (1) CU23475A1 (es)
CY (1) CY1114201T1 (es)
DK (1) DK1787653T3 (es)
ES (1) ES2389126T3 (es)
HR (1) HRP20120682T1 (es)
MX (1) MX2007000339A (es)
MY (1) MY150858A (es)
PL (1) PL1787653T3 (es)
PT (1) PT1787653E (es)
RS (1) RS52448B (es)
RU (1) RU2396274C2 (es)
SI (1) SI1787653T1 (es)
WO (1) WO2006005268A2 (es)
ZA (1) ZA200700178B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587139C (en) * 2004-11-23 2014-05-27 Zymogenetics, Inc. Purification of recombinant human factor xiii
CN101675355B (zh) 2007-05-04 2017-04-19 皇家飞利浦电子股份有限公司 具有对由mr线圈导致的辐射吸收进行校正的混合mr/pet
CU23950B1 (es) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
CN109295041A (zh) * 2018-10-10 2019-02-01 宁波希诺亚海洋生物科技有限公司 具有舍雷肽酶活性的多肽及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JP2611206B2 (ja) * 1985-11-15 1997-05-21 武田薬品工業株式会社 遺伝子およびその利用方法
KR100252197B1 (ko) * 1997-09-20 2000-04-15 박호군 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
US20040185566A1 (en) * 2003-03-19 2004-09-23 Peter Salamone Polypeptides toxic to nematodes and methods of use

Also Published As

Publication number Publication date
ZA200700178B (en) 2008-06-25
CY1114201T1 (el) 2016-08-31
AU2005262159A1 (en) 2006-01-19
PL1787653T3 (pl) 2012-11-30
RS52448B (sr) 2013-02-28
WO2006005268A2 (es) 2006-01-19
CA2572984A1 (en) 2006-01-19
PT1787653E (pt) 2012-09-06
WO2006005268A3 (es) 2006-03-09
BRPI0513136A (pt) 2008-04-29
AR050255A1 (es) 2006-10-11
DK1787653T3 (da) 2012-09-17
US20110218138A1 (en) 2011-09-08
ES2389126T3 (es) 2012-10-23
JP4914350B2 (ja) 2012-04-11
EP1787653A2 (en) 2007-05-23
HRP20120682T1 (hr) 2012-09-30
AU2005262159B2 (en) 2011-08-18
MY150858A (en) 2014-03-14
US8076297B2 (en) 2011-12-13
SI1787653T1 (sl) 2012-10-30
RU2396274C2 (ru) 2010-08-10
RU2007104776A (ru) 2008-08-20
JP2008505129A (ja) 2008-02-21
KR101365056B1 (ko) 2014-02-21
CA2572984C (en) 2014-12-09
MX2007000339A (es) 2007-03-12
KR20070042542A (ko) 2007-04-23
EP1787653B1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
AR105816A2 (es) Derivados de exendina-4 funcionalizada
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
MX383644B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
CL2011003333A1 (es) El compuesto n-{1s-[2r-(6,6'-difluoro-3'-{4s-hidroxi-1-[2s-(2s-metilamino-propionilamino)-butiril]-pirrolidin-2r-ilmetil}-1h,1'h-[2,2']biindolil-3-ilmetil)-4s-hidroxi-pirrolidin-1-carbonil]-propil}-2s-metilamino-propionamida; composicion farmaceutica; procedimiento de preparacion; compuestos intermediarios; utiles en el tratamiento de un trastorno proliferativo, tal como cancer, entre otros.
BRPI0607326B8 (pt) composição de vacina, uso da referida composição e kit em partes
GT200900126A (es) Novedosos anticuerpos antiproliferacion
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
CO6400198A2 (es) Composiciones y metodos novedosos
BR112015000183A2 (pt) proteínas de superfície específicas de variante (vsp) de protozoário como carreadores para entrega de fármaco oral
BR112014024358A2 (pt) uso de iduronate-2-sulfatase por via subcutânea e kit
CU23475A1 (es) Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
CA2449284A1 (en) Alpha-fetoprotein peptides and uses thereof
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
AR057565A1 (es) Interferon alfa y c- ficocianina para el tratamiento de enfermedades auoinmunes alergicas y cancer
GB0507598D0 (en) Composition
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo
WO2007101222A3 (en) Cancer treatment